良性前立腺肥大症（BPH）治療薬の世界及び中国市場

• 英文タイトル：Global and China Benign Prostatic Hyperplasia (BPH) Drugs Market Insights, Forecast to 2027

• レポートコード：QY2108PAL8777 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、141ページ • 納品方法：Eメール（納期：1日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の当調査資料ではグローバルにおける良性前立腺肥大症（BPH）治療薬の市場規模（2016年-2027年）と動向についてまとめました。中国市場については主要プレイヤーの市場シェア、良性前立腺肥大症（BPH）治療薬の種類別市場規模（アルファ遮断薬、ホスホジエステラーゼ5型阻害剤、その他）、用途別市場規模（病院、ドラッグストア、その他）も掲載しています。他に、北米・アメリカ市場、ヨーロッパ市場、アジア太平洋・日本市場、中南米市場、中東・アフリカ市場の市場規模、グローバル市場機会・課題・リスク要因、バリューチェーン・販売チャネル、主要プレイヤーの情報なども掲載しています。 ・調査の概要 ・調査のサマリー ・世界の良性前立腺肥大症（BPH）治療薬市場動向 ・グローバル主要プレイヤーの競争状況・市場シェア ・世界における良性前立腺肥大症（BPH）治療薬の種類別市場規模（2016年-2027年）：アルファ遮断薬、ホスホジエステラーゼ5型阻害剤、その他 ・世界における良性前立腺肥大症（BPH）治療薬の用途別市場規模（2016年-2027年）：病院、ドラッグストア、その他 ・良性前立腺肥大症（BPH）治療薬の中国市場分析 - 良性前立腺肥大症（BPH）治療薬の中国市場規模（2016年-2027年） - 中国における良性前立腺肥大症（BPH）治療薬の主要プレイヤー別市場シェア - 中国における良性前立腺肥大症（BPH）治療薬の種類別市場規模：アルファ遮断薬、ホスホジエステラーゼ5型阻害剤、その他 - 中国における良性前立腺肥大症（BPH）治療薬の用途別市場規模：病院、ドラッグストア、その他 ・良性前立腺肥大症（BPH）治療薬の北米市場（2016年-2027年） ・良性前立腺肥大症（BPH）治療薬のヨーロッパ市場（2016年-2027年） ・良性前立腺肥大症（BPH）治療薬のアジア太平洋市場（2016年-2027年） ・良性前立腺肥大症（BPH）治療薬の中南米市場（2016年-2027年） ・良性前立腺肥大症（BPH）治療薬の中東・アフリカ市場（2016年-2027年） ・主要プレイヤーの情報：Eli Lilly、GlaxoSmithKline、Astellas Pharma、Sanofi、Pfizer、Abbott、Allergan、TEVA、Mylan、Novartis、Merck ・市場機会・課題・リスク要因分析 ・バリューチェーン・販売チャネル分析 ・...

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man’s life. BPH most often occurs during this second growth phase.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

Market Analysis and Insights: Global and China Benign Prostatic Hyperplasia (BPH) Drugs Market
This report focuses on global and China Benign Prostatic Hyperplasia (BPH) Drugs market.
In 2020, the global Benign Prostatic Hyperplasia (BPH) Drugs market size was US$ 3294 million and it is expected to reach US$ 3513.4 million by the end of 2027, with a CAGR of 0.9% during 2021-2027. In China the Benign Prostatic Hyperplasia (BPH) Drugs market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Benign Prostatic Hyperplasia (BPH) Drugs Scope and Market Size
Benign Prostatic Hyperplasia (BPH) Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Benign Prostatic Hyperplasia (BPH) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Benign Prostatic Hyperplasia (BPH) Drugs market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.

Segment by Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
The classification of Benign Prostatic Hyperplasia (BPH) Drugs includes Alpha-Blocker, Phosphodiesterase Type-5 Inhibitors and Others. And the proportion of M Alpha-Blocker in 2019 is about 38%.

Segment by Application
Hospitals
Drugstores
Others
Benign Prostatic Hyperplasia (BPH) Drugs is widely used in Hospitals, Drugstores and Others. The most proportion of Benign Prostatic Hyperplasia (BPH) Drugs is used in Hospitals, and the proportion in 2019 is 48.97%.

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck

レポート目次

---

1 Study Coverage
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Market by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size, Estimates and Forecasts
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2016-2027
2.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2027
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Historical Market Size by Region (2016-2021)
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2022-2027)
2.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2022-2027)

3 Global Benign Prostatic Hyperplasia (BPH) Drugs Competitor Landscape by Players
3.1 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers by Sales
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2021)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers by Revenue
3.2.1 Key Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Covered: Ranking by Revenue
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2016-2021)
3.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia (BPH) Drugs Revenue in 2020
3.2.6 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturers
3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution, Product Types
3.4.1 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2016-2027)
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2016-2021)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2021)
4.1.3 Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Type (2022-2027)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2022-2027)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2022-2027)
4.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) Forecast by Type (2022-2027)

5 Breakdown Data by Application (2016-2027)
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (2016-2021)
5.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021)
5.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2016-2021)
5.1.3 Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2016-2021)
5.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Application (2022-2027)
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2022-2027)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Application (2022-2027)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Application (2022-2027)

6 China by Players, Type and Application
6.1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth 2016-2027
6.1.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth 2016-2027
6.1.2 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY Growth 2016-2027
6.1.3 China Benign Prostatic Hyperplasia (BPH) Drugs Market Share in Global Market 2016-2027
6.2 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Players (International and Local Players)
6.2.1 China Top Benign Prostatic Hyperplasia (BPH) Drugs Players by Sales (2016-2021)
6.2.2 China Top Benign Prostatic Hyperplasia (BPH) Drugs Players by Revenue (2016-2021)
6.3 China Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Review by Type (2016-2021)
6.3.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
6.3.2 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2016-2021)
6.3.3 China Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2016-2021)
6.4 China Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Type (2022-2027)
6.4.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2022-2027)
6.4.2 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2022-2027)
6.4.3 China Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Type (2022-2027)
6.5 China Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Review by Application (2016-2021)
6.5.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
6.5.2 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2016-2021)
6.5.3 China Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2016-2021)
6.6 China Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Application (2022-2027)
6.6.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2022-2027)
6.6.2 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Application (2022-2027)
6.6.3 China Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Application (2022-2027)

7 North America
7.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth 2016-2027
7.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
7.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021)
7.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada

8 Asia Pacific
8.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth 2016-2027
8.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Region
8.2.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021)
8.2.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam

9 Europe
9.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth 2016-2027
9.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
9.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021)
9.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy

10 Latin America
10.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth 2016-2027
10.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
10.2.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021)
10.2.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina

11 Middle East and Africa
11.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021)
11.2.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 UAE

12 Company Profiles
12.1 Eli Lilly
12.1.1 Eli Lilly Corporation Information
12.1.2 Eli Lilly Description and Business Overview
12.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.1.5 Eli Lilly Recent Development
12.2 GlaxoSmithKline
12.2.1 GlaxoSmithKline Corporation Information
12.2.2 GlaxoSmithKline Description and Business Overview
12.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.2.5 GlaxoSmithKline Recent Development
12.3 Astellas Pharma
12.3.1 Astellas Pharma Corporation Information
12.3.2 Astellas Pharma Description and Business Overview
12.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.3.5 Astellas Pharma Recent Development
12.4 Sanofi
12.4.1 Sanofi Corporation Information
12.4.2 Sanofi Description and Business Overview
12.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.4.5 Sanofi Recent Development
12.5 Pfizer
12.5.1 Pfizer Corporation Information
12.5.2 Pfizer Description and Business Overview
12.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.5.5 Pfizer Recent Development
12.6 Abbott
12.6.1 Abbott Corporation Information
12.6.2 Abbott Description and Business Overview
12.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.6.5 Abbott Recent Development
12.7 Allergan
12.7.1 Allergan Corporation Information
12.7.2 Allergan Description and Business Overview
12.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.7.5 Allergan Recent Development
12.8 TEVA
12.8.1 TEVA Corporation Information
12.8.2 TEVA Description and Business Overview
12.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.8.5 TEVA Recent Development
12.9 Mylan
12.9.1 Mylan Corporation Information
12.9.2 Mylan Description and Business Overview
12.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.9.5 Mylan Recent Development
12.10 Novartis
12.10.1 Novartis Corporation Information
12.10.2 Novartis Description and Business Overview
12.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.10.5 Novartis Recent Development
12.11 Eli Lilly
12.11.1 Eli Lilly Corporation Information
12.11.2 Eli Lilly Description and Business Overview
12.11.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.11.5 Eli Lilly Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
13.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
13.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
13.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Benign Prostatic Hyperplasia (BPH) Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Alpha-Blocker
Table 3. Major Manufacturers of Phosphodiesterase Type-5 Inhibitors
Table 4. Major Manufacturers of Others
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application (2021-2027) & (M Units)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region (M Units) & (US$ Million), 2016 VS 2021 VS 2027
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions (2016-2021) & (M Units)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions (2016-2021)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions (2016-2021) & (US$ Million)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2022-2027) & (M Units)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Region (2022-2027)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2016-2021) (M Units)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers (2016-2021)
Table 16. Ranking of Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers by Revenue (US$ Million) in 2020
Table 17. Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2016-2021) (US$ Million)
Table 18. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2016-2021)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2020)
Table 21. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Price (2016-2021) (US$/Unit)
Table 22. Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
Table 24. Date of International Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) (M Units)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2016-2021)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2021) (US$ Million)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2016-2021)
Table 30. Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) by Type (2016-2021) & (US$/Unit)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2022-2027) & (M Units)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type (2022-2027)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast V (2022-2027) & (US$ Million)
Table 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) Forecast by Type (2022-2027) & (US$/Unit)
Table 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) (M Units)
Table 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2016-2021)
Table 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2016-2021) (US$ Million)
Table 39. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2016-2021)
Table 40. Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) by Application (2016-2021) & (US$/Unit)
Table 41. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2022-2027) & (M Units)
Table 42. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Application (2022-2027)
Table 43. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 44. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Application (2022-2027)
Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) Forecast by Application (2022-2027) & (US$/Unit)
Table 46. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) of Key Companies (2016-2021)
Table 47. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Company (2016-2021)
Table 48. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Company (2016-2021)
Table 49. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Company (2016-2021)
Table 50. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2016-2021)
Table 51. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2016-2021)
Table 52. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Type (2016-2021)
Table 53. China Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2016-2021)
Table 54. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2022-2027)
Table 55. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2022-2027)
Table 56. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Type (2022-2027)
Table 57. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2022-2027)
Table 58. China Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2022-2027)
Table 59. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2016-2021)
Table 60. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2016-2021)
Table 61. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Application (2016-2021)
Table 62. China Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Application (2016-2021)
Table 63. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2022-2027)
Table 64. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2022-2027)
Table 65. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Application (2022-2027)
Table 66. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2022-2027)
Table 67. China Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Application (2022-2027)
Table 68. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 69. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
Table 70. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 71. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
Table 72. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021) & (M Units)
Table 73. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
Table 74. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 75. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2016-2021)
Table 76. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 77. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
Table 78. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 79. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
Table 80. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 81. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
Table 82. Latin Americaa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 83. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
Table 84. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 85. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
Table 86. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 87. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
Table 88. Eli Lilly Corporation Information
Table 89. Eli Lilly Description and Business Overview
Table 90. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 91. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 92. Eli Lilly Recent Development
Table 93. GlaxoSmithKline Corporation Information
Table 94. GlaxoSmithKline Description and Business Overview
Table 95. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 96. GlaxoSmithKline Product
Table 97. GlaxoSmithKline Recent Development
Table 98. Astellas Pharma Corporation Information
Table 99. Astellas Pharma Description and Business Overview
Table 100. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 101. Astellas Pharma Product
Table 102. Astellas Pharma Recent Development
Table 103. Sanofi Corporation Information
Table 104. Sanofi Description and Business Overview
Table 105. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 106. Sanofi Product
Table 107. Sanofi Recent Development
Table 108. Pfizer Corporation Information
Table 109. Pfizer Description and Business Overview
Table 110. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 111. Pfizer Product
Table 112. Pfizer Recent Development
Table 113. Abbott Corporation Information
Table 114. Abbott Description and Business Overview
Table 115. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 116. Abbott Product
Table 117. Abbott Recent Development
Table 118. Allergan Corporation Information
Table 119. Allergan Description and Business Overview
Table 120. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 121. Allergan Product
Table 122. Allergan Recent Development
Table 123. TEVA Corporation Information
Table 124. TEVA Description and Business Overview
Table 125. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 126. TEVA Product
Table 127. TEVA Recent Development
Table 128. Mylan Corporation Information
Table 129. Mylan Description and Business Overview
Table 130. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 131. Mylan Product
Table 132. Mylan Recent Development
Table 133. Novartis Corporation Information
Table 134. Novartis Description and Business Overview
Table 135. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 136. Novartis Product
Table 137. Novartis Recent Development
Table 138. Merck Corporation Information
Table 139. Merck Description and Business Overview
Table 140. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 141. Merck Product
Table 142. Merck Recent Development
Table 143. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
Table 144. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
Table 145. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
Table 146. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
Table 147. Benign Prostatic Hyperplasia (BPH) Drugs Customers List
Table 148. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020 & 2027
Figure 3. Alpha-Blocker Product Picture
Figure 4. Phosphodiesterase Type-5 Inhibitors Product Picture
Figure 5. Others Product Picture
Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020 & 2027
Figure 7. Hospitals
Figure 8. Drugstores
Figure 9. Others
Figure 10. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size 2016-2027 (US$ Million)
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2027 (M Units)
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Market Share by Region: 2021 Versus 2027
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
Figure 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2020
Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2016-2021)
Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in 2020
Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturer in 2020
Figure 20. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia (BPH) Drugs Revenue in 2020
Figure 21. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
Figure 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020
Figure 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2016-2021)
Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type in 2020
Figure 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Figure 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020
Figure 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2016-2021)
Figure 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application in 2020
Figure 30. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2016-2027 (M Units)
Figure 31. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2016-2027 (US$ Million)
Figure 32. China Benign Prostatic Hyperplasia (BPH) Drugs Market Share in Global Market 2016-2027
Figure 33. China 5 and 10 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue in Benign Prostatic Hyperplasia (BPH) Drugs in 2020
Figure 34. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2016-2021)
Figure 35. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate by Type in 2016 & 2020
Figure 36. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2016-2021)
Figure 37. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate by Application in 2016 & 2020
Figure 38. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2016-2021 (M Units)
Figure 39. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 40. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2020
Figure 41. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2020
Figure 42. U.S. Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 43. U.S. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 45. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2016-2021 (M Units)
Figure 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 48. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2020
Figure 49. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2020
Figure 50. Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 51. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 52. France Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 53. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 54. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 55. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 56. Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 57. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 58. Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 59. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 60. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2016-2021 (M Units)
Figure 61. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 62. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2020
Figure 63. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in 2020
Figure 64. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 65. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 66. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 67. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 68. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 69. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 70. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 71. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 72. Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 73. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 74. Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 75. Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 76. Indonesia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 77. Indonesia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 78. Thailand Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 79. Thailand Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 80. Malaysia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 81. Malaysia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 82. Philippines Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 83. Philippines Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 84. Vietnam Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 85. Vietnam Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 86. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2016-2021 (M Units)
Figure 87. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 88. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2020
Figure 89. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2020
Figure 90. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 91. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 92. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 93. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 94. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 95. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 96. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2016-2021 (M Units)
Figure 97. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 98. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2020
Figure 99. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2020
Figure 100. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 101. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 102. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 103. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 104. UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2021) (M Units)
Figure 105. UAE Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 106. Benign Prostatic Hyperplasia (BPH) Drugs Value Chain
Figure 107. Channels of Distribution
Figure 108. Distributors Profiles
Figure 109. Bottom-up and Top-down Approaches for This Report
Figure 110. Data Triangulation
Figure 111. Key Executives Interviewed

---